Subcutaneous daratumumab: an update on the latest MM clinical trials
Niels van de Donk
New applications for MRD measurement in myeloma: MRD 'over time'
The challenges facing elderly AML treatment
New targets to treat acute myeloid leukemia (AML) with FLT3 mutations
Making sense of the many treatment options for relapsed MM: cost-effectiveness